当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC
标题(英文)
Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC
条件
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
干预
Drug: Trastuzumab deruxtecan|Biological: Durvalumab|Drug: Cisplatin|Drug: Carboplatin|Drug: Pemetrexed